Prevention and treatment of mucositis: Development of patient specific oral care  by Mims, C.E. & Parker, E.E.
Marrow Transplant pediatric PCA by proxy protocol. This proto-
col represents a collaborative reevaluation and multidisciplinary
team effort. The two major priorities of this group were to main-
tain patient safety and ensure adequate pain management. The
results of this effort will be shared. The key components of the plan
include appropriate patient selection, parental education on PCA
by proxy, parental pain assessment and documentation, and eval-
uation of the safety and effectiveness of the intervention. This
presentation is based on our experience from July 1996 to Septem-
ber 2005 and includes 869 transplants in pediatric patients (median
age of 6.1 years) of whom 373 patients were under the age of 4
years. The vast majority of these patients beneﬁted from PCA by
proxy. There were no reported serious adverse events in these
patients.
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TIMELINE OF RISKS FOR INFECTIONS FOLLOWING Allo BMT: A CUT-
TING EDGE TOOL DESIGNED FOR NURSES
Austria-Granada, M.R. The University of Texas MD Anderson Cancer
Center, Houston, TX.
Infectious complications continue to pose enormous challenges
to the health care professionals experienced in treating the immu-
nocompromised population. After Allogeneic Bone Marrow
Transplantation (BMT), the presence of graft versus host disease
impairs the immune system, thereby delaying the host defenses’
ability to ﬁght invasive microorganisms. According to researchers,
life-threatening infections occur approximately in 30 % of alloge-
neic BMT patients, resulting in an increasing cause for concern
among clinicians. Nurses, as advocates and educators, are faced
with many questions from patients and their caregivers regarding
the risks and the steps to avoid exposure and occurrence of any
illness. As members of the health care team, they have a signiﬁcant
role in the assessment, evaluation, and management of allogeneic
BMT patients who are most vulnerable to pathogens. Their strong
knowledge base of the infectious process is integral in providing
immediate interventions, therefore, preventing secondary conse-
quences and unnecessary treatments that will affect the patients’
overall survival. A tool was developed to assist nurses to recognize
the common infections and drug therapies used in the 3 crucial
stages of the transplant process, namely: pre-engraftment (0-30
days post BMT), post-engraftment (30-100 days post BMT), and
late post engraftment (100 days post BMT). It is utilized as a
communication plan ensuring that BMT patients receive appro-
priate monitoring during their entire course of treatment. It also
serves as a framework of reference not only for BMT nurses, but
ﬂoat nurses and students as well. Most importantly, this instrument
beneﬁts nurses to better comprehend and carry out their essential
roles utilizing the knowledge and the skills they possess to effec-
tively and safely deliver the highest quality of nursing care.
A tool citing the common infections, treatments and nursing
responsibilities in the three time periods after Allogeneic BMT will
be presented.
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EMPOWERING MOBILITY IN ALLOGENEIC PATIENTS: AN ESSENTIAL
KEY TO COMBAT STEROID MYOPATHY
Estrella, J.M.E. The University of Texas M. D. Anderson Cancer
Center, Houston, TX.
Nurses play an important role in the recovery of allogeneic
transplant patients. A holistic approach enables nurses to address
the needs of patients who are faced with issues arising from recov-
ery of counts, prevention of infection, and their biggest challenge
yet, minimizing the complications of graft-versus-host disease
(GVHD). Studies reveal that 50% have a risk developing acute or
chronic GVHD despite use of anti-rejection drugs. Steroid therapy
is the frontline treatment for GVHD and is tapered depending on
response to the treatment and improvement of symptoms. Steroid
myopathy is essentially ubiquitous among patients with GVHD
and the most effective way to treat it is to eliminate or decrease the
dose of steroids. Unfortunately, when GVHD ﬂares up and ste-
roids are resumed, steroid myopathy recurs and the vicious cycle
goes on. Constant mobility during the entire transplant process
lessens the incidence of steroid myopathy. It is essential that a
physical/occupational therapy (PT/OT) consult be obtained once
high doses of steroids are initiated. Rehabilitation starts upon
admission, thus, the future goal for BMT is to incorporate Physical
Medicine and Rehabilitation into the patient’s plan of care. The
BMT nurse’s goal is to empower and encourage patients to remain
mobile and maintain activities of daily living. At our comprehen-
sive cancer center, ambulation around the unit is promoted at least
3 times a day—a mile each time or as tolerated. Gait is the physical
activity most known and better adapted to improve physical status.
Moreover, range of motion, resistive or endurance exercises are
also utilized in accordance to the PT/OT regimen. Upon dis-
charge, patients are also encouraged to participate in out-patient
rehabilitation programs. A case study will be presented, including
a chart that describes the nursing interventions and various devices
used at our institution reﬂecting the rehabilitation care provided to
patients with steroid myopathy.
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ADMINISTRATION OF IV IMMUNOSUPPRESSIVE AGENTS AND THE
DRAWING OF THEIR LEVELS: A HOW TO GUIDE FOR NURSES
Lahr, S.L. Froedtert Hospital, Milwaukee, WI.
Topic: To show the importance of dedicating a line to admin-
ister immunosuppressive drugs (ISD) to ensure proper dosing for
the BMT patient. Purpose/Background/Rationale: Early in
2005, Froedtert Hospital (FH) experienced several patients who
had continuously high ISD levels without showing signs of toxicity
or decreasing lab values after dose reduction. At this point, it was
decided the nurses needed to draw both a peripheral level and level
from the central venous catheter (CVL) in order to see if the 2
levels correlated. Up until this point, it had been our policy to draw
all levels from the CVL only. In all of the patients where dual labs
were drawn, the CVL level was signiﬁcantly higher than the level
drawn peripherally. This discrepancy has many negative conse-
quences including poor immunosuppression for the BMT patient,
possible increase in the rate of GVHD, unnecessary changes in
drug dosages and inaccurate lab data. This poster will describe the
nursing interventions taken to correct this problem showing that
dedicating a line is an important part of insuring accurate lab and
dosing levels when it is not possible to draw a peripheral level.
Intervention: Nurse interviews and audits showed signiﬁcant vari-
ance in the knowledge of the ISD policy. Once initial data was
collected policy changes included the drawing of peripheral levels
only with continued line dedication. Staff was reeducated on
proper procedure and documentation. Procedure reminders were
placed in areas of patient care. Evaluation: Dual labs are again
being drawn to see if post education data shows an increased
correlation between peripheral and CVL values. Preliminary re-
sults show that there has been a signiﬁcant improvement. Discus-
sion: This presentation will demonstrate that continuity in nursing
practice will insure the proper dosing of the BMT patient unable
to receive a peripheral blood draw.
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PREVENTION AND TREATMENT OF MUCOSITIS: DEVELOPMENT OF
PATIENT SPECIFIC ORAL CARE
Mims, C.E., Parker, E.E. UAB Hospital, Birmingham, AL.
Oral mucositis is a condition that ranges in severity from redness
to severe ulceration. It is a severe and painful complication that
occurs in patients receiving high dose chemotherapy prior to bone
marrow or stem cell transplantation. Mucositis remains one of the
most under treated problems in patients with cancer. It has been
rated as the most debilitating side effect by patients with cancer
undergoing bone marrow transplantation. Oral care is necessary
prior to chemotherapy as well as throughout the course of therapy
for any patient with cancer at risk for developing mucositis. Al-
though there are many pharmacologic interventions available,
there is not a universally accepted strategy used to reduce the
incidence of mucositis or treat active mucositis. This can make it
challenging for clinicians to choose the most effective mouth care
Transplant Nursing
160
regimen for patients. Prevention and/or reduction of mucositis
should start with the development of a standardized oral care
regimen that will be used consistently in the clinical management
of the patient. Mouth care protocols should also be simple and easy
to perform in order to ensure that patients will be compliant with
an oral care regimen. The goal is to determine the most effective
treatment available to prevent mucositis, treat the signs and symp-
toms of mucositis, and provide information to be used to develop
a new oral care standard for patients in the BMT unit at UAB.
Currently, all patients receiving a BMT at UAB regardless of their
diagnosis or chemotherapy regimen are placed on the same mouth
care protocol, which is to be used every four hours. This protocol
includes biotine, chlorhexadine, sucralfate, and nystatin. According
to the nurses in the BMT unit, patients do not consistently use the
mouth care provided. Patients complain that there are too many
steps involved, report an unpleasant taste, nausea, and anxiety
when it is time to do mouth care. During 2004, 12 out of 77
patients at UAB had grade 3 mucositis and 42 out of 77 had grade
2 mucositis. Recommendations were made for high- risk patients
(identiﬁed prior to receiving chemotherapy) to receive an aggres-
sive oral care protocol, including the use of palifermin. All low-risk
patients would receive saline rinses, or salt water and baking soda
solutions in order to prevent or treat mucositis.
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VENO OCCULSIVE DISEASE: A POTENTIALLY LIFE THREATENING COM-
PLICATION OF HEMATOPOIETIC STEM CELL TRANSPLANTATION
Summers, E., Edmisten, J., Martin, P.L., Frey, M., Kurtzberg, J.
Pediatric Blood and Marrow Transplant Program at Duke University
Medical Center, Durham, NC.
Veno Occlusive disease (VOD) is a potentially life threatening
liver complication occurring in up to 5% of patients undergoing
hematopoietic stem cell transplantation (HSCT). It usually occurs
before day 35 post transplant and presents with signs and symp-
toms including painful hepatomegaly, jaundice, ﬂuid retention,
weight gain of 	5%, and ascites. Patients with VOD consume
platelets, are often refractory to platelet transfusions and become
coagulopathic. VOD occurs when the blood vessels of the liver
become swollen and congested, diminishing the liver’s ability to
remove toxins and waste from the blood. Fluids may build up in the
liver causing additional swelling and tenderness (Mullaly K., 2002).
Duke Low dose heparin infused continuously for the ﬁrst 28 days
post transplant  actigall can be used as prophylaxis against VOD.
Patients at high risk for VOD may be identiﬁed during the trans-
plant workup and include those with prior liver disease, iron
overload, decreased protein C, and heavily pretreated patients with
malignancies. An attempt is made to avoid the use of hepatotoxic
agents, but radiation, cytoxan, and busulfan are frequently neces-
sary to treat the patient’s underlying disease. The use of deﬁb-
rotide, an investigational agent with local thrombolytic activity,
appears to be a safe and effective treatment options for patients
with VOD. Studies have reported up to 50% of children respond-
ing favorably to treatment with deﬁbrotide when signiﬁcant VOD
has occurred. Nurses play an important role in diagnosing VOD in
pediatric patients by ﬁrst monitoring strict IOs, daily weights, and
pain reported by the patients on assessment. The purpose of this
poster is to: (1) describe the signs and symptoms of Veno Occlusive
disease; (2) state the treatment modalities currently used for treat-
ment and prevention of VOD; and (3) describe important aspects
of nursing care of the pediatric patient with VOD.
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THE DEVELOPMENT OF AN ALGORITHM MANAGING ACUTE DELIRIUM
IN PATIENTS UNDERGOING ALLOGENEIC STEM CELL TRANSPLANT
(SCT)
Shelburne, N.F., Simpson, K.K., Bevans, M.F. National Institutes of
Health, Clinical Center, Bethesda, MD.
Delirium is deﬁned as an acute and ﬂuctuating disruption of
attention and cognition that is not accounted for by preexisting
dementia. Fann et al (2002) reports that up to 50% of recipients
undergoing a SCT experience delirium. Pretreatment predictors of
delirium have been identiﬁed in oncology patients, which are
frequently present in SCT recipients, in addition to the direct and
indirect effects of their intense treatment. Negative outcomes as-
sociated with delirious behavior can include increased length of
stay, and injuries related to falls or other self inﬂicted behaviors.
Current literature focuses on the identiﬁcation of predictors and
reliable recognition of delirium. Minimal information is available
to guide the use of interventions to avoid negative consequences.
The purpose of this project was to develop a standardized approach
to improve the recognition of delirium, identify SCT patients at
high risk for delirium, and guide nursing interventions to decrease
complications.
The Delirium Intervention Algorithm was activated with 15
SCT inpatients during a 3-month time period, including 5 (33%)
myeloablative, and 10 (66%) nonmyeloablative. Three (20%) pa-
tients experienced acute delirium, and 9 (75%) were identiﬁed at
high risk for delirium. One (11%) high risk patient experienced a
fall. High risk patients experienced elevations in kidney and liver
function, narcotic and benzodiazepine use, and alterations in
mood/affect. The application of the Delirium Intervention Algo-
rithm improved the care of SCT patients by guiding nurses in the
early recognition of delirium, the identiﬁcation and removal of
contributing factors, and the use of interventions to ensure patient
safety and maintain dignity. Implementation of this standardized
approach to patient care empowers the nurse to effectively reduce
length of stay and morbidity in SCT recipients at risk for compli-
cations from delirium.
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STRONGYLOIDES STERCORALIS IN THE IMMUNOCOMPROMISED POP-
ULATION
Rivera, Z.R., Massaro, A. University of Texas M. D. Anderson Cancer
Center, Houston, TX.
Blood Marrow Transplant (BMT) patients are typically immu-
nocompromised for prolonged periods. Due to a compromised
immune system, BMT patients are susceptible to acquiring oppor-
tunistic infections. Infectious organisms may include parasites such
as Toxoplasma gondii, Pneumocystis carinii, Entamoeba coli, and more
infrequently Strongyloides stercoralis.
Strongyloides stercoralis is an intestinal nematode of humans esti-
mated affecting tens of millions of persons worldwide. This para-
site is endemic in tropical or temperate and subtropical climates.
Risk factors may include travel to those areas. S. stercoralis can
transform into a fulminant fatal illness in certain conditions asso-
ciated with a compromised host. With the increased mortality and
morbidity associated with S. stercoralis focusing on identifying,
screening, and treating those at risk is warranted. Of the individ-
uals who are infected with S. stercoralis, 50% are asymptomatic and
75% manifest eosinophilia. Clinical symptoms include epigastric
pain and tenderness, diarrhea, nausea and vomiting, constipation,
and weight loss. In BMT patients, there may be an acceleration of
the autoinfection cycle which can result in hyperinfection syn-
drome and/or disseminated strongyloidiasis increasing the high
probability of multi-organ system invasion. Treatment goals of
patients with S. stercoralis are directed toward preventing hyperin-
fection and dissemination, as well as complete eradication. Three
oral preparations are available for use in uncomplicated intestinal
strongyloidiasis, these include: thiabendazole, albendazole, and
ivermectin. Multi-dose scheduled regimens may be necessary. Ed-
ucational opportunities should focus on increasing clinician’s
knowledge about clinical manifestations, diagnosis/pathogenesis,
and treatment of this infrequent infection to facilitate earlier rec-
ognition of and/or surveillance for infection in high-risk patients.
A case study of a BMT patient will be presented.
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PATIENT ACCESS: ENHANCING THE REFERRAL PROCESS
Cruz, E.D., Kersten, B.R., Wallis, C.G., Basquez, S.H., Hsu, Y. The
University of Texas M. D. Anderson Cancer Center, Houston, TX.
Patient Access is a vital factor in obtaining new patients and
achieving high levels of Referring Physician (RP) satisfaction in a
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